ARS Pharmaceuticals (SPRY) Total Liabilities (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Total Liabilities data on file, last reported at $226.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 130.07% year-over-year to $226.3 million; the trailing twelve-month figure through Mar 2026 stood at $226.3 million (up 130.07% YoY), and the FY2025 full-year result was $213.4 million, up 126.16% from the prior year.
• Total Liabilities improved to $226.3 million in Q1 2026, from $213.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $226.3 million in Q1 2026 to a low of $2.4 million in Q4 2023.
• A 5-year average of $63.9 million and a median of $15.2 million in 2022 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities slumped 80.47% in 2022 and jumped 3786.12% in 2024, its largest moves.
• Tracing SPRY's Total Liabilities over 5 years: stood at $8.5 million in 2022, then plunged by 71.6% to $2.4 million in 2023, then jumped by 3786.12% to $94.4 million in 2024, then soared by 126.16% to $213.4 million in 2025, then climbed by 6.03% to $226.3 million in 2026.
• Business Quant data shows SPRY's Total Liabilities at $226.3 million in Q1 2026, $213.4 million in Q4 2025, and $225.1 million in Q3 2025.